Levebon (Levetiracetam)

Levetiracetam is employed to manage seizure disorders within the antiepileptic drug class, targeting abnormal neuronal firing that leads to convulsions.

• Partial seizures: reduces frequency of focal onset seizures, helping patients achieve better seizure control.
• Generalized tonic‑clonic seizures: decreases occurrence of bilateral convulsive episodes, improving safety and daily functioning.
• Myoclonic seizures: lessens rapid muscle jerks, contributing to improved quality of life.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces excessive synaptic firing and neuronal excitability, thereby diminishing the propagation of epileptic discharges throughout the central nervous system. The precise downstream pathways remain under investigation, but the net effect is a decrease in hypersynchronous activity that underlies seizure generation. Clinical studies have shown that this mechanism provides broad-spectrum efficacy across multiple seizure types.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: transient feeling of light‑headedness or imbalance.
• Fatigue: unusual tiredness or lack of energy.
• Headache: mild to moderate pain in the head region.
• Nausea: sensation of queasiness, sometimes leading to vomiting.

Serious or Rare Side Effects

• Severe skin reactions: includes Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention.
• Mood alterations: depression, anxiety, or suicidal ideation may occur and should be reported promptly.
• Blood disorders: neutropenia, thrombocytopenia, or anemia can develop, necessitating laboratory monitoring.

When prescribing Levebon, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess creatinine clearance and adjust dose in impaired patients.
• Hepatic function: monitor liver enzymes, especially in patients with existing liver disease.
• Psychiatric status: observe for new or worsening depression, anxiety, or suicidal thoughts.
• Pregnancy: potential risks are unknown; discuss benefits versus risks with the patient.
• Concomitant CNS depressants: may enhance sedation; use with caution.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levebon can interact with other medicines, affecting its plasma concentration or enhancing side effects.

Major Interactions (Avoid)

• Carbamazepine: strong enzyme inducer that can markedly lower levetiracetam levels.
• Phenytoin: induces metabolism, potentially reducing therapeutic efficacy.
• Phenobarbital: increases clearance, leading to subtherapeutic concentrations.

Moderate Interactions (Monitor Closely)

• Alcohol: additive central nervous system depression may increase drowsiness.
• Benzodiazepines: combined use can enhance sedative effects, requiring dose adjustments.